| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:GP29
CAS:1415050-59-7
Package:50mg/RMB 13800;100mg/RMB 17500;25mg/RMB 10600
|
Benzamide, N-[3-[2-[[4-[2-(acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)- manufacturers
- GP29
-
- $1980.00 / 50mg
-
2026-01-05
- CAS:1415050-59-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Benzamide, N-[3-[2-[[4-[2-(acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)- Basic information |
| | Benzamide, N-[3-[2-[[4-[2-(acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)- Chemical Properties |
| density | 1.334±0.06 g/cm3(Predicted) | | pka | 12.88±0.70(Predicted) |
| | Benzamide, N-[3-[2-[[4-[2-(acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)- Usage And Synthesis |
| Description | GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease. It acts by targeting the ATP-binding pocket of IRE1α. | | Uses | IRE1α kinase-IN-10 (GP29) is an IRE1α kinase inhibitor. IRE1α kinase-IN-10 can be used for the research of endoplasmic reticulum stress-related diseases[1]. | | References | [1] Wang L, et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012 Dec;8(12):982-9. DOI:10.1038/nchembio.1094 |
| | Benzamide, N-[3-[2-[[4-[2-(acetylamino)ethoxy]phenyl]amino]-6-quinazolinyl]-4-methylphenyl]-3-(trifluoromethyl)- Preparation Products And Raw materials |
|